Lead Product(s) : Fruquintinib,Sintilimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR -1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis and designed to improve kinase selectivity with the intention of minimizing off-target toxi...
Product Name : Elunate
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2023
Lead Product(s) : Fruquintinib,Sintilimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fanregratinib Tartrate,Toripalimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The first stage of the study is a dose escalation phase to determine the dose limiting toxicity (DLT) and recommended Phase II dose (“RP2D”) of HMPL-453 in combination with chemotherapy (gemcitabine and cisplatin) or toripalimab.
Product Name : HMPL-453
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 02, 2022
Lead Product(s) : Fanregratinib Tartrate,Toripalimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Surufatinib,Etoposide,Toripalimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sulanda (Surufatinib), a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptors and fibroblast growth factor receptor.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 12, 2021
Lead Product(s) : Surufatinib,Etoposide,Toripalimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fruquintinib,Tislelizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This is an open-label, multi-center, non-randomized study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally advanced or metastatic TNBC or advanced EC.
Product Name : Elunate
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2021
Lead Product(s) : Fruquintinib,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable